López-Maraver M, Serrano-Combarro A, Atienza-Mateo B, Del Val N, Casafont-Solé I, Melero-Gonzalez RB, Pérez-Linaza A, Calvo Gutiérrez J, Mena-Vázquez N, Vegas-Revenga N, Domínguez-Casas L, Loarce Martos J, Peralta Ginés CA, Diez Morrondo C, Pérez Albaladejo L, López Sánchez R, Manzano Canabal MG, Brandy-García AM, López Viejo P, Bonilla G, Maiz-Alonso O, Carrasco-Cubero C, Garijo Bufort M, Moreno M, Urruticoechea-Arana A, Ordóñez-Palau S, González-Montagut C, Giner Serret E, De Dios Jiménez De Aberasturi JR, Lozano Morillo F, Vázquez Rodríguez T, Carreira PE, Blanco Madrigal JM, Miguel Ibáñez B, Rodríguez López M, Fernández-Díaz C, Loricera J, Ferraz-Amaro I, Ferrer-Pargada D, Castañeda S, and Blanco R
Background: Evidence on abatacept (ABA) utility for rheumatoid arthritis (RA) - associated interstitial lung disease (ILD) is growing. Clinical trials have shown equivalence in subcutaneous (SC) and intravenous (IV) administration of ABA for articular manifestations. However, this has not been studied in respiratory outcomes., Objective: To compare the effectiveness of ABA in RA-ILD patients according to the route of administration., Methods: National retrospective multicentre study of RA-ILD patients on treatment with ABA. They were divided into 2 groups: a) IV, and b) SC. The following outcomes were analysed from baseline to final follow-up using linear mixed models: a) forced vital capacity (FVC), b) diffusing capacity of the lungs for carbon monoxide (DLCO), c) chest high resolution computed tomography (HRCT), d) dyspnoea, e) RA activity, and f) sparing corticosteroids effect., Results: A total of 397 patients were included (94 IV-ABA and 303 SC-ABA), median follow-up of 24 [10-48] months. After adjustment for possible confounders, FVC and DLCO remained stable during the first 24 months without differences between IV-ABA and SC-ABA (p = 0.6304 and 0.5337). Improvement/ stability of lung lesions in HRCT was observed in 67 % of patients (75 % IV-ABA, 64 % SC-ABA; p = 0.07). Dyspnoea stabilized/ improved in 84 % of patients (90 % IV-ABA, 82 % SC-ABA; p = 0.09). RA - disease activity improved in both groups. No statistically significant differences regarding any of the variables studied between the two groups were found. ABA was withdrawn in 87 patients (21.9 %), 45 % IV-ABA and 37 % SC-ABA (p = 0.29). ILD worsening and articular inefficacy were the most common reasons for ABA discontinuation., Conclusion: In patients with RA-ILD, ABA seems to be equally effective regardless of the route of administration., Competing Interests: Declaration of competing interest Disclosures that may be interpreted as constituting of possible conflict(s) of interest for the study: B. A.-M. received grants/research supports from Abbvie and Roche and had consultation fees/participation in company-sponsored speaker´s bureau from Pfizer, Celgene, Novartis, Sanofi, Janssen, UCB and Lilly, outside the submitted work; N.V.-R. has received fees in company-sponsored speaker's bureau and research supports from AbbVie, Lilly, Celgene, Grünenthal, UCB Pharma, Nordic Pharma, MSD and Rubió; L.C.D.-C has received research supports and participation in company-sponsored speaker's bureau from Abbvie, Janssen, Lilly and Celgene; J.L.M has received fees in company-sponsored speaker's bureau from Boehringer Ingelheim, Bristol-Myers Squibb (BMS) and Galapagos and had consultation fees from Boehringer Ingelheim; G.B has received fees in company-sponsored speaker's bureau from Bristol-Myers Squibb (BMS); A.U.-A. has received grants/research supports from Abbvie, Galápagos, Novartis, GSK, Astrazeneca, Janssen, Pfizer and Amgen; C.F.-D. has received fees in company-sponsored speaker's bureau from: Janssen, Galápagos, Amgen, Bristol Myers Squibb (BMS); I. F.-A. has received grants/research supports from Abbott, MSD, Janssen, and Roche, as well as consultation fees from company sponsored speakers bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and MSD; S.C. has received research supports from MSD and Pfizer and had consultation fees/participation in company-sponsored speaker's bureau from Amgen, BMS, Eli-Lilly, MSD, Roche, and UCB. S. C. is also assistant professor of the cátedra EPID-Future, funded by UAM-Roche, Universidad Autónoma de Madrid (UAM), Spain; R. B. received grants/research support from AbbVie, MSD, and Roche, and had consultation fees/participation in a company-sponsored speaker's bureau from AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD. The rest of the authors have declared no conflicts of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)